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adults [4, 5]. Most individuals affected by myocarditis remain asymptomatic, and the disease spontaneously resolves frequently; however, 10–20 % of the patients with myocarditis—an estimated 20,000 to 40,000
patients per year in the USA—can develop chronic disease leading to dilated cardiomyopathy (DCM), with
an incidence of 3.5 to 8.5 cases per 100,000 population,
or 9,000 to 20,000 new cases annually [6, 7]. Approximately half of DCM patients undergo heart transplantation due to lack of available, effective therapeutic options. The estimated cost of caring for DCM patients is
$7 billion annually in the USA alone [8, 9]. Two lines
of evidence exist to suggest that inflammatory infiltrates can be present in the hearts of healthy individuals to a low degree: (1) Myocarditis is suspected to be
the cause in 5–22 % of sudden deaths in athletes less
than 35 years old [4, 10–12] and (2) a necropsy study
involving more than 12,000 accidental deaths revealed
the presence of inflammatory infiltrates in the hearts of
1.06 % of individuals [13]. But what triggers myocarditis in these apparently healthy individuals is a fundamental question to be addressed in cardiology research.
Accumulated literature suggests that the genesis of
myocarditis requires the mediation of a variety of immune cells of both the innate (natural killer T cells, γδ T
cells, mast cells) and adaptive immune systems (CD4 T
cells, CD8 T cells, and B cells) involving multiple mechanisms or pathways [2, 14]. In this review, we discuss
how environmental microbes can cause myocarditis by
molecular mimicry.

Abstract
Heart disease, the leading cause of death in humans, is
estimated to affect one in four American adults in some
form. One predominant cause of heart failure in young
adults is myocarditis, which can lead to the development of dilated cardiomyopathy, a major indication for
heart transplantation. Environmental microbes, including viruses, bacteria, and fungi that are otherwise innocuous, have the potential to induce inflammatory heart
disease. As the list is growing, it is critical to determine
the mechanisms by which microbes can trigger heart
autoimmunity and, importantly, to identify their target antigens. This is especially true as microbes showing
structural similarities with the cardiac antigens can predispose to heart autoimmunity by generating cross-reactive immune responses. In this review, we discuss the
relevance of molecular mimicry in the mediation of infectious myocarditis.
Keywords: heart, infectious myocarditis, autoimmunity,
molecular mimicry, coxsackievirus, microbial mimics,
mimicry epitopes
Introduction
Heart disease is the leading cause of death in humans
[1]. An estimated 80 million American adults (one in
four) have some form of cardiovascular disease [1, 2],
with a projected incidence of 40.5 % by 2030 [3]. Myocarditis is a predominant cause of heart failure in young
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Environmental Microbes in the Causation of
Myocarditis
Generally, it is believed that microbial infections can
trigger autoimmune responses in genetically susceptible individuals. However, unlike other diseases caused
by known specific etiologies, it is practically difficult to
prove all of the Koch’s postulates for autoimmune diseases [15]. Furthermore, a theme is now emerging to
suggest that exposure to multiple microbes, rather than
a single microbe, may be critical to initiate autoimmune
diseases [15]. Mechanistically, microbes that primarily infect the target organ can lead to secondary generation of autoimmune responses by facilitating the release
of intracellular self-antigens, which are then recognized
by the immune system as foreign antigens. A variety of
pathogens like viruses, bacteria, rickettsia, and parasites
have been implicated in the causation of myocarditis
(reviewed in reference [2]), but their direct causal links
remain tenuous clinically, with the challenge being able
to prove the cause-and-effect relationship.
One mechanism by which microbes can break self-tolerance is by inducing cross-reactive immune responses
through molecular mimicry because of their antigenic
similarities with host proteins (reviewed in references
[6, 16]). Cross-reactivity can occur for antibodies and/
or T cells [6, 16, 17]. For antibodies, cross-reactivity has
been noted for linear sequences containing amino acids identical to the self-antigens, and also for homologous, but non-identical sequences, including for epitopes, derived from unrelated molecules such as proteins
and carbohydrates [18]. For T cells however, cross-reactivity occurs as a result of degeneracy in the recognition
of peptides displayed by major histocompatibility complex (MHC) molecules (Fig. 1). T cell degeneracy can occur for microbial peptides sharing stretches of amino
acids significantly identical to self-antigens or even for
those peptides bearing the minimal sequence identities,
so long the critical MHC- and T cell receptor (TCR)-contact residues are preserved [19]. While, the autoantibodies produced by B cells can activate complement cascade
leading to the induction of type II and type III hypersensitivity reactions, the CD4 helper T cells and cytotoxic
T lymphocytes (CTLs) mediate their effects through the
production of cytokines and cytolysis, respectively [20].
Association of Autoimmunity in Diseases Caused
by Common Infectious Pathogens of Cardiovascular
System
Evidence from Human Studies
In at least four examples, autoimmunity can be an important component of cardiovascular diseases caused
by infectious agents: coxsackievirus B (CVB)3 in postinfectious myocarditis [21], Trypanosoma cruzi in Chagas heart disease [22], Chlamydia in myocarditis and

Figure 1. Mechanistic basis for TCR degeneracy. αβ TCR-expressing
CD4 T cells recognize peptide fragments presented in the context of
class II MHC molecules by antigen-presenting cells. The side chains
of some amino acids in the peptide sequence are extended. Such residues preferentially anchor MHC molecules, which are commonly
referred as MHC-anchor residues (bottom arrows: solid, primary;
dotted, secondary). Similarly, side chains of solvent-exposed residues also can interact with TCRs, and they are called TCR contact
residues (top arrows: solid, primary; dotted, secondary). Substitutions, if any, in the primary positions can lead to complete ablation
of the T cell response, but similar substitutions are tolerable for secondary TCR contact residues [90]. Such precise recognition has been
demonstrated in the case of the hemoglobin (Hb) molecule, where a
single amino acid substitution at the primary TCR contact site (glutamic acid 73) in Hb 64–76 resulted in 1,000-fold weaker recognition
by the T cells [90]. Such an event can occur for two entirely different ligands, if the primary T cell contact residue alone is preserved
in both. For example, in the transgenic mouse model of spontaneous
rheumatoid arthritis, a TCR specific for bovine ribonuclease 42–56
can recognize another irrelevant ligand, glucose-6-phosphate isomerase 281–293, which is a self-peptide [90]. Thus, enormous potential exists for microbes that bear the sequences of self-antigens to
induce cross-reactive T cell responses, as long as the critical MHCand TCR-interacting residues are preserved.

coronary artery disease [23, 24], and β-hemolytic streptococci in rheumatic heart disease (RHD) [25–28].
Coxsackieviruses are generally implicated as causes of
myocarditis in North America [29]. In the USA, approximately five million enterovirus infections are attributed
to CVB1–5, and 12 % of those may have myocardial involvement, in which CVB1, CVB3, and CVB5 serotypes
are commonly implicated [30, 31]. Serologically, CVB3reactive antibodies are found in about 50 % of DCM patients, while enterovirus genomic material can be detected in up to 70 % [32–34], suggesting CVB3-mediated
autoimmunity can play a role in myocarditis/DCM
pathogenesis. Isolation of infectious CVB particles is not
commonly reported in patients with myocarditis/DCM
as the myocardial biopsies are taken mostly in rare cases
[35]. But, when isolated for example at necropsy, the viral
isolates were found to be pathogenic in mice [36].
Chagas heart disease caused by T. cruzi is the leading
cause of infectious myocarditis in the world [37]. Autoimmunity is suspected in the disease pathology, and autore-
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activity appears to reside in the CD4 T cell compartment,
although CD8 T cells outnumber CD4 T cells in heart infiltrates (3:1) [38, 39]. By deriving T cell clones and antibodies from patients with Chagas disease, reactivities
were observed for various cardiac proteins including cardiac myosin, and also for antigenic epitopes from T. cruzi
proteins such as B13, cysteine protease cruzipain, and ribosomal proteins P1 and P2. But their disease-inducing
potential remains to be tested experimentally [38, 40, 41].
Chlamydial myocarditis characterized by subclinical
or asymptomatic phenotype has been noted in 5–15 % of
the individuals’ positive for Chlamydia psittaci infection.
Likewise, two other chlamydial species are also implicated in the causation of myocarditis, namely Chlamydia
pneumoniae and Chlamydia trachomatis, where C. pneumoniae appears to induce more severe disease than C.
trachomatis [42, 43]. The underlying autoimmune mechanisms in chlamydial infections, if any, are unknown.
In group A streptococcal infections, the concept
of molecular mimicry has been implicated as a major
mechanism of disease pathogenesis. Antibodies and
T cells specific to streptococcal M protein have been
shown to cross-react with host protein, cardiac myosin, and M protein [26, 27]. A cytotoxic human monoclonal antibody against the group A carbohydrate epitope
N-acetyl-β-d-glucosamine generated from rheumatic
carditis patient has delineated the sharing of epitopes
between the group A streptococcus, cardiac myosin,
and the valve endothelium, basement membrane, and
laminin [44]. The basis of this mimicry is the alpha helical structures of the shared molecules [45]. Also, peptide epitopes of human cardiac myosin have been identified in RHD [46]. Antibodies in rheumatic carditis are
believed to damage the valve endothelium in human
disease leading to edema of the valve and activation of
the endocardium and T cell infiltration in the valve [47].
Thus, mimicry is believed to play a role in attacking the
heart valve through both antibodies and T cells in human rheumatic carditis. Furthermore, T cell clones derived from intralesional fragments from patients with
RHD react with three different regions within the streptococcal protein M5, as well as cardiac proteins derived
from valvular tissue, and the immunodominant epitope
of M5 protein has been localized to a region spanning
the amino acids 81–103 [48–50]. Similarly, T cell clones
recognizing other peptide regions of M5, namely B2 and
B3A, can react with S2 and light meromyosin regions
of human cardiac myosin, suggesting that the immune
pathogenesis of RHD involves the mediation of cross-reactive T cell responses potentially for a broad spectrum
of cardiac antigens [18, 27, 48, 50].
Interestingly, molecular mimicry has not been limited to cross-reactivity between host and pathogen,
but has been extended to include antibodies generated
against one host antigen (cardiac myosin or its peptide
fragment S2-16 from the S2 hinge region) which can
cross-react with another host antigen, β-adrenergic re-
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ceptor-1 (BAR), possibly leading to apoptosis of cardiomyocytes via the cyclic adenosine monophosphate-dependent protein kinase A signaling pathway [51, 52].
Such an effect by antibodies which signal receptors on
cardiomyocytes could be blocked by human cardiac myosin and β-adrenergic blocker [51]. Likewise, cardiac adenine nucleotide translocator 1 (ANT) and anti-CVB3
antibodies can cross-react with each other, suggesting a
role for ANT autoantibodies in CVB3/DCM pathogenesis [53], possibly by altering the functional activities of
ANT (e.g., energy metabolism) [54, 55]. Thus, antibodies which affect the physiology and function of the heart
may be important in leading to altered heart function
and arrhythmias in cardiomyopathy.
Evidence from Animal Models
Animal models are useful tools to delineate the autoimmune events in various diseases caused by infectious pathogens. One such model is experimental autoimmune myocarditis (EAM), and the EAM models
are valuable because their histological features bear resemblance to post-infectious myocarditis induced with
pathogens like CVB3 [56, 57]. The disease is induced in
susceptible strains of rodents by immunizing the animals with cardiac proteins, such as cardiac myosin
heavy chain-α (Myhc-α), and cardiac troponin I or their
peptide fragments [58–60]. The immune pathogenesis of
EAM is typically described as delayed-type hypersensitivity reaction that involves the mediation of T cells
and macrophages. Although Myhc-α is located intracellularly, its peptide fragments have been found to be
displayed by antigen-presenting cells in several mouse
strains (C.B-17, SCID, B10.D2, DBA/2J, and A/J) leading to the recognition of myosin peptides by T cells [58,
61]. Using Myhc-α 334–352 as a putative antigen, we recently attempted to identify the microbes that have the
potential to trigger myocardial injuries by molecular
mimicry. We identified three novel microbial agents—
Cryptococcus neoformans, Bacillus spp. (BAC), and Magnetospirillum gryphiswaldense—that carry the mimicry sequence for Myhc-α 334–352 [62]. The mimicry epitopes
induce lymphocytic myocarditis in A/J mice reminiscent of the disease induced with Myhc-α 334–352, indicating that exposure to these microbes might predispose
to heart autoimmunity [62].
CVB3 is one of the bona fide pathogens of cardiovascular system being used in the myocarditis research. Infection studies with CVB3 in mice have shown that the
disease course exhibit two distinct stages that occur in
continuum similar to the biphasic nature of the disease
in humans [63, 64]: the acute phase (14–18 days postinfection), in which infectious virus is present causing
damage to cardiac myocytes, and the chronic phase (beyond 18 days postinfection), in which inflammation reappears, although the extent of virus replication is much
reduced due to selection of a defective virus [56, 65].
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Previously, it was shown that the severity of CVB3-induced myocarditis was relatively high in mice deficient
for CD8, but the disease was attenuated in mice deficient for CD4. Conversely, the mice deficient for both
CD8 and CD4 were better protected, suggesting that
both cell types modulate the disease outcome [66]. Evidence of autoimmunity in CVB3 infection was first provided based on the observation that the CTLs generated in Balb/C mice infected with CVB3 were lytic to
cardiomyocytes, and the CTLs were capable of inducing the disease in naïve mice, but their antigen-specificity was unknown [67, 68]. Using MHC class II/IAk dextramers for Myhc-α 334–352, we recently showed that
the post-infectious myocarditis induced with CVB3 in
A/J mice is accompanied by the generation of pathogenic cardiac myosin-specific CD4 T cells that can transfer disease into naïve recipients [69]. We are currently
investigating whether CVB3 infection also can lead to
the generation of T cells that react with other cardiac
antigens, and if so, whether these are pathogenic. Such
a possibility exists because CVB3 infection is accompanied by the generation of antibodies for several cardiac antigens [70, 71]. Whether molecular mimicry hypothesis is relevant to CVB3 pathogenesis continues to
be uncertain as there are no significant sequence identities between CVB3 proteome and a well-characterized
cardiac antigen, Myhc-α. But, the recent data suggest
that CVB3 infection can possibly lead to the generation
of cross-reactive antibodies for actin because certain degree of sequence homology exists between the two [72].
Likewise, whether the virus that can persist in defective
form [65], reactivates, and aggravates disease as a result
of viral damage of cardiac tissue is unknown.
In experimental Chagas heart disease, immunization of mice with T. cruzi proteins led to the induction of
cross-reactive immune responses to cardiac myosin [73].
Likewise, the animals immunized with cardiac myosin
also showed parasite-reactive immune response [38, 74].
Consistent with these observations, tolerance studies also
suggest that cardiac myosin might be the primary autoantigen recognized in Chagas heart disease [73, 74]. Recent data, however, indicate that other antigens such as
BAR and muscarinic cholinergic (MC) receptors also may
be targeted in the progression of Chagas heart disease as
autoantibodies generated against BAR and MC receptors
reacted with T. cruzi ribosomal proteins [75, 76].
As to the chlamydial infections, peptides from cysteine-rich outer membrane protein—C. trachomatis serovar
E (ChTR1) 25–40; C. trachomatis serovar C (ChTR2) 25–
40; C. trachomatis serovars L1, L2, and L3 (ChTR3) 25–
40; C. pneumoniae (ChPN) 25–40; and C. psittaci (ChPS)
25–40—were found to share sequence identities with
Myhc-α [23]. By active immunization, the mimicry epitopes induced comparable myocarditis in mice accompanied with the generation of cross-reactive T cells and
antibodies [23, 77]. However, in infection studies, although animals infected with Chlamydia showed myo-
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carditis and heart-specific antibodies [23, 78], it was not
clear whether the antibodies were produced secondarily
as a result of recognition of cardiac antigens released
following bacterial damage to the heart tissue or as a
consequence of molecular mimicry. Regardless of their
mechanisms however, the disease-inducing abilities
of cardiac antibodies produced in the infected animals
has not been tested in the adoptive transfer protocols.
Likewise, whether the animals infected with chlamydia
show the generation of pathogenic cardiac-reactive T
cells also has not been investigated. This is a fundamental question to be addressed because T cell help is critical for production of antibodies. Thus, whether autoimmune response contributes to the pathogenesis of
chlamydial myocarditis continues to be debated.
The relevance of molecular mimicry in the pathogenesis of RHD induced by streptococci has been well-studied in various rodent models. Antibodies against the
group A streptococcal carbohydrate epitope, N-acetylβ-d-glucosamine, have been shown to recognize alpha
helical sequences [45, 79, 80] and represent mimicry between two dissimilar structures. Anti-group A streptococcal antibodies can also cross-react with both CVB3
and cardiac myosin [81, 82]. These cross-reactive immune responses were shown to be pathogenic in the
mouse model of CVB3 infection [83]. Mouse monoclonal antibodies that recognize the motif QKSKQ within
the streptococcal proteins M5 and M6 can react predominantly with Myhc-α [84], and other proteins, such
as tropomyosin, laminin, vimentin, and keratin, may
play a role in group A streptococcal cross-reactivities
with heart and other tissues [44, 45, 79, 81, 85–87]. Studies in mice suggested that T cells against streptococcal
M proteins are pathogenic and have been shown to react with the myocarditogenic peptide NT4 from streptococcal M5 protein which can cross-react with cardiac
myosin and CVB3 [83], and the severity of viral myocarditis is reduced in mice tolerized with NT4 peptide
[25, 83]. Similarly, streptococcal M protein and/or certain M protein peptides were shown to induce valvulitis
in rats [88] and myocarditis in mice [83, 89]. Molecular
mimicry although is thought of as a disease process can
also be part of the normal immune response to protect
against pathogens, as the mechanism dictates “survival
of the fittest.” For example, an antibody recognizing
both host and multiple microbial ligands can be thought
of as “killing two birds with one stone” as the host protects itself using an antibody which neutralizes multiple pathogens. Studies have demonstrated this principle
when mouse monoclonal antibodies generated against
the group A streptococcus also neutralized CVB3 and
were cytotoxic for heart cells [81].
Conclusion
The general belief is that environmental microbes,
mostly viruses, can trigger autoimmune diseases in ge-
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netically susceptible individuals; the challenge is being able to establish their cause and effect relationship.
More recent data suggest that exposure to environmental microbes of non-viral origin carrying the sequences
identical to Myhc-α, which are otherwise innocuous
like BAC, has the potential to trigger heart autoimmunity through molecular mimicry. But a formal proof is
needed to verify whether such a phenomenon can occur
in humans. Likewise, whether exposure to multiple microbes is required to trigger heart autoimmunity also is
not known. This can be addressed in animal models by
exposing the myocarditis-susceptible animals to different microbes sequentially like CVB3 followed by BAC
or vice versa. To this end, we are setting up an infection
model with BAC. Our preliminary data suggest that A/J
mice infected with BAC show the generation of Myhcα-reactive T cells (unpublished observations). Although
translating the information generated in animal models
to humans is challenging, the growing list of microbes
of non-viral origin as potential candidates for heart autoimmunity may create opportunities to target them
therapeutically.
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